07 September 2018 | News
The ARESupa diagnostic test will be designed to detect nearly all types of pathogens in a variety of samples.
Image credit- testtargettreat.com
Ares Genetics, a division of German molecular diagnostics company Curetis, has initiated the development of a new diagnostic test to detect microbial infections and predict responses to antimicrobial therapies.
The new ARESupa Universal Pathogenome Assay will include Curetis’ ARES Technology Platform and genetic antimicrobial resistance database, called ARESdb, for interpreting results.
The ARES Technology Platform is based on next-generation sequencing (NGS), while ARESdb is an artificial intelligence (AI) powered genetic pathogen reference database.
The ARESupa diagnostic test will be designed to detect nearly all types of pathogens in a variety of samples. The test is also expected to be able to use a single laboratory workflow to predict response to different antimicrobial drugs.
It will be initially offered as a laboratory test, with plans to obtain regulatory approvals for use as an in-vitro diagnostic (IVD) and subsequent commercialisation.